GlassScriptPhysician profile
Rajiv T Philip
NPI 1063601045
$2,315.26
in general payments reported to CMS, 2019-2025
25 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $67.92 · 2021: $156 · 2022: $80.11 · 2023: $288 · 2024: $270 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.65 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.28 | 2019-2025 | Jascayd, Spiriva Respimat, Ofev |
| Merck Sharp & Dohme LLC | $307.77 | 2019-2025 | Recarbrio, Zerbaxa |
| Glaxosmithkline, LLC. | $248.44 | 2020-2025 | Nucala, Trelegy Ellipta |
| La Jolla Pharmaceutical Company | $247.71 | 2023-2024 | Giapreza |
| Astrazeneca Pharmaceuticals LP | $152.55 | 2019-2025 | Tezspire |
| Insmed, INC. | $143.64 | 2025 | Brinsupri, Arikayce |
| Gilead Sciences, INC. | $122.29 | 2024 | Veklury |
| Verona Pharma, INC. | $102.92 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $100.87 | 2022-2025 | |
| Viatris Specialty LLC | $74.04 | 2025 | Yupelri |
| Pulmonx Corporation | $61.66 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Baxter Healthcare | $42.95 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $38.72 | 2022-2023 | Smartvest |
| Mallinckrodt Hospital Products INC. | $32.33 | 2020 | |
| Caris Mpi, INC. | $29.27 | 2025 | Mi Cancer Seek |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.13 | 2025 | Zepbound |
| Genentech USA, INC. | $23.01 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.98 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $19.90 | 2025 | Lumryz |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.64 | 2020 | |
| Philips North America LLC | $18.45 | 2025 | Vest Therapy Und |
| Cumberland Pharmaceuticals, INC. | $17.13 | 2022 | |
| United Therapeutics Corporation | $17.01 | 2025 | Tyvaso |
| Seqirus USA INC | $15.70 | 2021 | |
| Axsome Therapeutics, INC. | $13.87 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Philip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.